Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism

Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism: A Randomized, Double Blinded Study

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00535561

Enrollment

Unknown

Registered

2007-09-26

Start date

2007-06-30

Completion date

2007-09-30

Last updated

2012-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Deficiency Anemia, Subclinical Hypothyroidism

Keywords

iron deficiency anemia, anemia, hypothyroidism, subclinical hypothyroidism

Brief summary

To determine whether iron deficiency anemia can be an indication for the treatment of subclinical hypothyroidism.

Detailed description

51 Patients presented to our university outpatient internal medicine clinic who are found to have iron deficiency anemia coexisting with subclinical hypothyroidism have been included in this study. Patients were randomly assigned to oral iron or oral iron plus levothyroxin therapy. The physician and the patients did not know who received oral iron only or oral iron plus levothyroxine treatment. Hematologic parameters as well as serum iron, ferritin and iron binding capacity were being measured at the beginning and 3 months after treatment in both groups.

Interventions

DRUGFerrous sulfate tablets 325 mg, po, TID

DRUGFerrous sulfate plus levothyroxine

Combination of ferrous sulfate tablet 325mg plus levothyroxine tablet 25 micrograms, po, TID

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

23 Years to 73 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis and laboratory confirmation of iron deficiency anemia and subclinical hypothyroidism * Must be able to swallow tablets

Exclusion criteria

* Multifactorial anemia or anemia due to other reasons * Iron deficiency anemia requiring urgent intervention- cardiac ischemia, severe anemia, GI or GU losses due to malignancy and or acute/subacute big loses by respiratory, Gİ, GU, etc. system * Prior thyroid disorder and/or treatment history * Presence of any other co-morbid disease like renal insufficiency/ failure, coronary heart disease, hypertension, diabetes mellitus, any endocrine system disease other than subclinical hypothyroidism

Design outcomes

Primary

Measure	Time frame
Significant improvement in Hgb and RBC	3 months

Secondary

Measure	Time frame
Significant improvement in serum iron, ferritin, TIBC and possibly in serum TSH and free T4 levels.	3 months

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026